Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, remains a devastating disease. The purpose of this review is to highlight recent literature on mechanistic and translational developments that advance our understanding of a complex crosstalk between KRAS, YAP and Src tyrosine kinase family (SFK) in PDAC development and maintenance. We discuss recent studies indicating the importance of RAS dimerization in signal transduction and new findings showing that the potent pro-oncogenic members of the SFK phosphorylate and inhibit RAS function. These surprising findings imply that RAS may not play a crucial role in maintaining certain subtypes of PDAC. In support of this interpretation, current evidence indicates that the survival of the basal-like subtype of PDAC is less dependent on RAS but relies, at least in part, on the activity of YAP/TAZ. Based on current evidence, we propose that SFK propels PDAC cells to a state of high metastasis, epithelial-mesenchymal transition (EMT) and reduced dependence on KRAS signaling, salient features of the aggressive basal-like/squamous subtype of PDAC. Strategies for PDAC treatment should consider the opposite effects of tyrosine phosphorylation on KRAS and SFK/YAP in the design of drug combinations that target these novel crosstalk mechanisms and overcome drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 1×
“Furthermore, the benefit in prolonging survival by current neo-adjuvant and adjuvant chemotherapeutic regimens is modest and recurrences occur often [3,4].”
BackgroundMoffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“In the setting of PDAC and other cancers, the molecular mechanisms by which KRAS functions at the cell membrane to activate its effectors [35] are of intense interest and translational importance for drug discovery that remain incompletely understood.”
BackgroundRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 1×
“A major regulator of YAP/TAZ activity is the tumor suppressive Hippo pathway [96], which consists of a serine/threonine kinase cascade comprised by the mammalian sterile 20-like kinase 1 or 2 (MST1 or MST2), which binds and phosphorylates the scaffold protein Salvador homolog 1 (SAV1).”
BackgroundTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Research works printed but not linked: 115
- Siegel, 2021, Cancer statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 · DOI · Paper page
- Rahib, 2014, Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155 · DOI · Paper page
- Garcia-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., and Acedo, P. (2021). The state-of-the-art of phase ii/iii clinical trials for targeted pancreatic cancer therapies. J. Clin. Med., 10. · DOI
- Hammad, 2021, Pancreatic adenocarcinoma: Molecular drivers and the role of targeted therapy, Cancer Metastasis Rev., 40, 355, 10.1007/s10555-020-09948-w · DOI
- Eyres, 2021, Tet2 drives 5hmc marking of gata6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes, Gastroenterology, 161, 653, 10.1053/j.gastro.2021.04.044 · DOI
- Koikawa, 2021, Targeting pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy, Cell, 184, 4753, 10.1016/j.cell.2021.07.020 · DOI · Paper page
- Eibl, 2019, Kras, yap, and obesity in pancreatic cancer: A signaling network with multiple loops, Semin. Cancer Biol., 54, 50, 10.1016/j.semcancer.2017.10.007 · DOI · Paper page
- Bryant, 2014, Kras: Feeding pancreatic cancer proliferation, Trends Biochem. Sci., 39, 91, 10.1016/j.tibs.2013.12.004 · DOI · Paper page
- Rhett, 2020, Biology, pathology, and therapeutic targeting of ras, Adv. Cancer Res., 148, 69, 10.1016/bs.acr.2020.05.002 · DOI
- Dhanaraman, 2020, Rassf effectors couple diverse ras subfamily gtpases to the hippo pathway, Sci. Signal., 13, eabb4778, 10.1126/scisignal.abb4778 · DOI
- Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
- Ardito, 2012, Egf receptor is required for kras-induced pancreatic tumorigenesis, Cancer Cell, 22, 304, 10.1016/j.ccr.2012.07.024 · DOI · Paper page
- Maitra, 2005, Precursors to invasive pancreatic cancer, Adv. Anat. Pathol., 12, 81, 10.1097/01.pap.0000155055.14238.25 · DOI · Paper page
- Hingorani, 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell, 4, 437, 10.1016/S1535-6108(03)00309-X · DOI · Paper page
- Hingorani, 2005, Trp53r172h and krasg12d cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
- Ferreira, 2017, Duct- and acinar-derived pancreatic ductal adenocarcinomas show distinct tumor progression and marker expression, Cell Rep., 21, 966, 10.1016/j.celrep.2017.09.093 · DOI · Paper page
- Rozengurt, 2019, Central role of yes-associated protein and ww-domain-containing transcriptional co-activator with pdz-binding motif in pancreatic cancer development, World J. Gastroenterol., 25, 1797, 10.3748/wjg.v25.i15.1797 · DOI
- Kim, 2021, Oncogenic kras recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis, Cancer Discov., 11, 2094, 10.1158/2159-8290.CD-20-1228 · DOI · Paper page
- Rudack, 2021, The ras dimer structure, Chem. Sci., 12, 8178, 10.1039/D1SC00957E · DOI
- Rajakulendran, 2009, A dimerization-dependent mechanism drives raf catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
- Nussinov, 2019, Is nanoclustering essential for all oncogenic kras pathways? Can it explain why wild-type kras can inhibit its oncogenic variant?, Semin. Cancer Biol., 54, 114, 10.1016/j.semcancer.2018.01.002 · DOI
- Terrell, 2019, Ras-mediated activation of the raf family kinases, Cold Spring Harb. Perspect. Med., 9, a033746, 10.1101/cshperspect.a033746 · DOI · Paper page
- Lavoie, 2015, Regulation of raf protein kinases in erk signalling, Nat. Rev. Mol. Cell Biol., 16, 281, 10.1038/nrm3979 · DOI · Paper page
- Tran, 2021, Kras interaction with raf1 ras-binding domain and cysteine-rich domain provides insights into ras-mediated raf activation, Nat. Commun., 12, 1176, 10.1038/s41467-021-21422-x · DOI · Paper page
- Brummer, 2020, Raf kinase dimerization: Implications for drug discovery and clinical outcomes, Oncogene, 39, 4155, 10.1038/s41388-020-1263-y · DOI
- Van, Q.N., Prakash, P., Shrestha, R., Balius, T.E., Turbyville, T.J., and Stephen, A.G. (2021). Ras nanoclusters: Dynamic signaling platforms amenable to therapeutic intervention. Biomolecules, 11. · DOI
- Guha, 2003, Neurotensin stimulates protein kinase c-dependent mitogenic signaling in human pancreatic carcinoma cell line panc-1, Cancer Res., 63, 2379
- Mueller, 2018, Evolutionary routes and kras dosage define pancreatic cancer phenotypes, Nature, 554, 62, 10.1038/nature25459 · DOI · Paper page
- Rozengurt, 2018, Yes-associated protein (yap) in pancreatic cancer: At the epicenter of a targetable signaling network associated with patient survival, Signal Transduct. Target. Ther., 3, 11, 10.1038/s41392-017-0005-2 · DOI · Paper page
- Je, 2014, The inhibition of src family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion, Pancreas, 43, 768, 10.1097/MPA.0000000000000103 · DOI · Paper page
- Ortiz, 2021, Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition, Cell Commun. Signal., 19, 67, 10.1186/s12964-021-00750-x · DOI · Paper page
- Buday, 2020, Novel regulation of ras proteins by direct tyrosine phosphorylation and dephosphorylation, Cancer Metastasis Rev., 39, 1067, 10.1007/s10555-020-09918-2 · DOI
- Bunda, 2014, Src promotes gtpase activity of ras via tyrosine 32 phosphorylation, Proc. Natl. Acad. Sci. USA, 111, E3785, 10.1073/pnas.1406559111 · DOI · Paper page
- Huang, 2020, Ptpn2 regulates the activation of kras and plays a critical role in proliferation and survival of kras-driven cancer cells, J. Biol. Chem., 295, 18343, 10.1074/jbc.RA119.011060 · DOI
- Fodor, 2018, Dual allosteric inhibition of shp2 phosphatase, ACS Chem. Biol., 13, 647, 10.1021/acschembio.7b00980 · DOI · Paper page
- Rozengurt, 2014, Suppression of feedback loops mediated by pi3k/mtor induces multiple overactivation of compensatory pathways: An unintended consequence leading to drug resistance, Mol. Cancer Ther., 13, 2477, 10.1158/1535-7163.MCT-14-0330 · DOI · Paper page
- Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat. Med., 17, 500, 10.1038/nm.2344 · DOI · Paper page
- Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 · DOI · Paper page
- Martens, 2019, Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications, Ann. Oncol., 30, 1428, 10.1093/annonc/mdz181 · DOI
- Martinelli, 2017, Gata6 regulates emt and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer, Gut, 66, 1665, 10.1136/gutjnl-2015-311256 · DOI · Paper page
- Duan, 2021, The value of gata6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer, Sci. Rep., 11, 14951, 10.1038/s41598-021-94544-3 · DOI
- Birnbaum, 2021, Transcriptomic analysis of laser capture microdissected tumors reveals cancer- and stromal-specific molecular subtypes of pancreatic ductal adenocarcinoma, Clin. Cancer Res., 27, 2314, 10.1158/1078-0432.CCR-20-1039 · DOI
- Juiz, 2020, Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype, FASEB J., 34, 12214, 10.1096/fj.202000363RR · DOI · Paper page
- Milan, 2021, Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: A tale of two cell types and their many variants, EMBO J., 40, e107206, 10.15252/embj.2020107206 · DOI
- Hayashi, 2020, A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma, Nat. Cancer, 1, 59, 10.1038/s43018-019-0010-1 · DOI · Paper page
- Miyabayashi, 2020, Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes, Cancer Discov., 10, 1566, 10.1158/2159-8290.CD-20-0133 · DOI · Paper page
- Singh, 2009, A gene expression signature associated with “k-ras addiction” reveals regulators of emt and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
- Chen, 2021, Emerging strategies to target ras signaling in human cancer therapy, J. Hematol. Oncol., 14, 116, 10.1186/s13045-021-01127-w · DOI · Paper page
- Kerk, 2021, Metabolic networks in mutant kras-driven tumours: Tissue specificities and the microenvironment, Nat. Rev. Cancer, 21, 510, 10.1038/s41568-021-00375-9 · DOI · Paper page
- Kanai, 2000, Taz: A novel transcriptional co-activator regulated by interactions with 14-3-3 and pdz domain proteins, EMBO J., 19, 6778, 10.1093/emboj/19.24.6778 · DOI · Paper page
- Santinon, 2016, Control of yap/taz activity by metabolic and nutrient-sensing pathways, Trends Cell Biol., 26, 289, 10.1016/j.tcb.2015.11.004 · DOI · Paper page
- Zanconato, 2019, Yap and taz: A signalling hub of the tumour microenvironment, Nat. Rev. Cancer, 19, 454, 10.1038/s41568-019-0168-y · DOI · Paper page
- Thompson, 2020, Yap/taz: Drivers of tumor growth, metastasis, and resistance to therapy, Bioessays, 42, e1900162, 10.1002/bies.201900162 · DOI · Paper page
- Park, 2019, Switch-like enhancement of epithelial-mesenchymal transition by yap through feedback regulation of wt1 and rho-family gtpases, Nat. Commun., 10, 2797, 10.1038/s41467-019-10729-5 · DOI · Paper page
- Greenhough, 2018, Cancer cell adaptation to hypoxia involves a hif-gprc5a-yap axis, EMBO Mol. Med., 10, e8699, 10.15252/emmm.201708699 · DOI · Paper page
- Gundogdu, R., and Hergovich, A. (2019). Mob (mps one binder) proteins in the hippo pathway and cancer. Cells, 8. · DOI
- Wang, 2014, Interplay of mevalonate and hippo pathways regulates rhamm transcription via yap to modulate breast cancer cell motility, Proc. Natl. Acad. Sci. USA, 111, E89
- Zheng, 2015, Identification of happyhour/map4k as alternative hpo/mst-like kinases in the hippo kinase cascade, Dev. Cell, 34, 642, 10.1016/j.devcel.2015.08.014 · DOI · Paper page
- Meng, 2015, Map4k family kinases act in parallel to mst1/2 to activate lats1/2 in the hippo pathway, Nat. Commun., 6, 8357, 10.1038/ncomms9357 · DOI · Paper page
- Hergovich, A. (2016). The roles of ndr protein kinases in hippo signalling. Genes, 7. · DOI · Paper page
- McCollum, 2018, Angiomotins stimulate lats kinase autophosphorylation and act as scaffolds that promote hippo signaling, J. Biol. Chem., 293, 18230, 10.1074/jbc.RA118.004187 · DOI
- Höffken, V., Hermann, A., Pavenstädt, H., and Kremerskothen, J. (2021). Wwc proteins: Important regulators of hippo signaling in cancer. Cancers, 13. · DOI
- Plouffe, 2018, The hippo pathway effector proteins yap and taz have both distinct and overlapping functions in the cell, J. Biol. Chem., 293, 11230, 10.1074/jbc.RA118.002715 · DOI · Paper page
- Moroishi, 2015, The emerging roles of yap and taz in cancer, Nat. Rev. Cancer, 15, 73, 10.1038/nrc3876 · DOI · Paper page
- Kaan, 2017, Crystal structure of taz-tead complex reveals a distinct interaction mode from that of yap-tead complex, Sci. Rep., 7, 2035, 10.1038/s41598-017-02219-9 · DOI · Paper page
- Strauss, 2015, Taz protein accumulation is negatively regulated by yap abundance in mammalian cells, J. Biol. Chem., 290, 27928, 10.1074/jbc.M115.692285 · DOI
- Yu, 2013, The hippo pathway: Regulators and regulations, Genes Dev., 27, 355, 10.1101/gad.210773.112 · DOI · Paper page
- Tiebe, 2012, Insulin/igf signaling drives cell proliferation in part via yorkie/yap, Dev. Biol., 367, 187, 10.1016/j.ydbio.2012.05.008 · DOI
- Wang, 2016, Biphasic regulation of yes-associated protein (yap) cellular localization, phosphorylation, and activity by g protein-coupled receptor agonists in intestinal epithelial cells: A novel role for protein kinase d (pkd), J. Biol. Chem., 291, 17988, 10.1074/jbc.M115.711275 · DOI
- Sudol, 2013, Yap1 oncogene and its eight isoforms, Oncogene, 32, 3922, 10.1038/onc.2012.520 · DOI
- Ben, 2020, Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of yap1, J. Biol. Chem., 295, 13965, 10.1074/jbc.RA120.013820 · DOI
- Cho, 2021, Hippo-independent regulation of yki/yap/taz: A non-canonical view, Front. Cell Dev. Biol., 9, 658481, 10.3389/fcell.2021.658481 · DOI
- Yang, 2013, Cdk1 phosphorylation of yap promotes mitotic defects and cell motility and is essential for neoplastic transformation, Cancer Res., 73, 6722, 10.1158/0008-5472.CAN-13-2049 · DOI · Paper page
- Cho, 2020, Cdk7 regulates organ size and tumor growth by safeguarding the hippo pathway effector yki/yap/taz in the nucleus, Genes Dev., 34, 53, 10.1101/gad.333146.119 · DOI
- Seo, 2019, Mk5 regulates yap stability and is a molecular target in yap-driven cancers, Cancer Res., 79, 6139, 10.1158/0008-5472.CAN-19-1339 · DOI
- An, 2020, Mst4 kinase suppresses gastric tumorigenesis by limiting yap activation via a non-canonical pathway, J. Exp. Med., 217, e20191817, 10.1084/jem.20191817 · DOI
- Moon, 2017, Phosphorylation by nlk inhibits yap-14-3-3-interactions and induces its nuclear localization, EMBO Rep., 18, 61, 10.15252/embr.201642683 · DOI · Paper page
- Xie, 2015, Hippo transducer taz promotes epithelial mesenchymal transition and supports pancreatic cancer progression, Oncotarget, 6, 35949, 10.18632/oncotarget.5772 · DOI
- Yang, 2015, Active yap promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through lpar3, Oncotarget, 6, 36019, 10.18632/oncotarget.5935 · DOI · Paper page
- Hernandez, 2017, Overexpression of yes associated protein 1, an independent prognostic marker in patients with pancreatic ductal adenocarcinoma, correlated with liver metastasis and poor prognosis, Pancreas, 46, 913, 10.1097/MPA.0000000000000867 · DOI
- Zhang, 2014, Downstream of mutant kras, the transcription regulator yap is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci. Signal., 7, ra42, 10.1126/scisignal.2005049 · DOI · Paper page
- Gruber, 2016, Yap1 and taz control pancreatic cancer initiation in mice by direct up-regulation of jak–stat3 signaling, Gastroenterology, 151, 526, 10.1053/j.gastro.2016.05.006 · DOI · Paper page
- Tamura, T., Kodama, T., Sato, K., Murai, K., Yoshioka, T., Shigekawa, M., Yamada, R., Hikita, H., Sakamori, R., and Akita, H. (2021). Dysregulation of pi3k and hippo signaling pathways synergistically induces chronic pancreatitis via ctgf upregulation. J. Clin. Invest., 131. · DOI
- Murakami, 2019, A yap-myc-sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in kras-driven pancreatic ductal adenocarcinomas, Dev. Cell, 51, 113, 10.1016/j.devcel.2019.07.022 · DOI · Paper page
- Murakami, 2017, Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma, Oncogene, 36, 1232, 10.1038/onc.2016.288 · DOI · Paper page
- King, 2020, Yap/taz promote the scavenging of extracellular nutrients through macropinocytosis, Genes Dev., 34, 1345, 10.1101/gad.340661.120 · DOI
- Park, 2020, Yap and ap-1 cooperate to initiate pancreatic cancer development from ductal cells in mice, Cancer Res., 80, 4768, 10.1158/0008-5472.CAN-20-0907 · DOI
- Liu, J., Gao, M., Nipper, M., Deng, J., Sharkey, F.E., Johnson, R.L., Crawford, H.C., Chen, Y., and Wang, P. (2019). Activation of the intrinsic fibroinflammatory program in adult pancreatic acinar cells triggered by hippo signaling disruption. PLoS Biol., 17. · DOI
- Park, 2015, Alternative wnt signaling activates yap/taz, Cell, 162, 780, 10.1016/j.cell.2015.07.013 · DOI · Paper page
- Bo, 2016, Upregulation of the expression of wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model, Mol. Med. Rep., 13, 1163, 10.3892/mmr.2015.4642 · DOI
- Lehmann, 2016, Zeb1 turns into a transcriptional activator by interacting with yap1 in aggressive cancer types, Nat. Commun., 7, 10498, 10.1038/ncomms10498 · DOI · Paper page
- Liu, 2021, Zinc-dependent regulation of zeb1 and yap1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer, Gastroenterology, 160, 1771, 10.1053/j.gastro.2020.12.077 · DOI · Paper page
- Krebs, 2017, The emt-activator zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer, Nat. Cell Biol., 19, 518, 10.1038/ncb3513 · DOI · Paper page
- Chang, 2018, The swi/snf complex is a mechanoregulated inhibitor of yap and taz, Nature, 563, 265, 10.1038/s41586-018-0658-1 · DOI · Paper page
- Raj, 2019, Reciprocal crosstalk between yap1/hippo pathway and the p53 family proteins: Mechanisms and outcomes in cancer, Front. Cell Dev. Biol., 7, 159, 10.3389/fcell.2019.00159 · DOI
- Saladi, 2017, Actl6a is co-amplified with p63 in squamous cell carcinoma to drive yap activation, regenerative proliferation, and poor prognosis, Cancer Cell, 31, 35, 10.1016/j.ccell.2016.12.001 · DOI · Paper page
- Lee, 2020, The tumor suppressor bap1 regulates the hippo pathway in pancreatic ductal adenocarcinoma, Cancer Res., 80, 1656, 10.1158/0008-5472.CAN-19-1704 · DOI
- Hasan, N., and Ahuja, N. (2019). The emerging roles of atp-dependent chromatin remodeling complexes in pancreatic cancer. Cancers, 11. · DOI
- Hao, 2017, Insulin receptor and gpcr crosstalk stimulates yap via pi3k and pkd in pancreatic cancer cells, Mol. Cancer Res., 15, 929, 10.1158/1541-7786.MCR-17-0023 · DOI · Paper page
- Kisfalvi, 2009, Metformin disrupts crosstalk between g protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth, Cancer Res., 69, 6539, 10.1158/0008-5472.CAN-09-0418 · DOI · Paper page
- Mayer, 2010, Advances in targeting src in the treatment of breast cancer and other solid malignancies, Clin. Cancer Res., 16, 3526, 10.1158/1078-0432.CCR-09-1834 · DOI · Paper page
- Roskoski, 2015, Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors, Pharmacol. Res., 94, 9, 10.1016/j.phrs.2015.01.003 · DOI · Paper page
- Moro, 2020, Epigenetic silencing of the ubiquitin ligase subunit fbxl7 impairs c-src degradation and promotes epithelial-to-mesenchymal transition and metastasis, Nat. Cell Biol., 22, 1130, 10.1038/s41556-020-0560-6 · DOI
- Parkin, 2019, Targeting the complexity of src signalling in the tumour microenvironment of pancreatic cancer: From mechanism to therapy, FEBS J., 286, 3510, 10.1111/febs.15011 · DOI
- Morton, 2010, Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma, Gastroenterology, 139, 292, 10.1053/j.gastro.2010.03.034 · DOI · Paper page
- Shields, 2011, Oncogenic ras/src cooperativity in pancreatic neoplasia, Oncogene, 30, 2123, 10.1038/onc.2010.589 · DOI · Paper page
- Dosch, 2019, Src kinase inhibition restores e-cadherin expression in dasatinib-sensitive pancreatic cancer cells, Oncotarget, 10, 1056, 10.18632/oncotarget.26621 · DOI
- Ye, 2015, Epithelial-mesenchymal plasticity: A central regulator of cancer progression, Trends Cell Biol., 25, 675, 10.1016/j.tcb.2015.07.012 · DOI · Paper page
- Si, 2017, Src inhibits the hippo tumor suppressor pathway through tyrosine phosphorylation of lats1, Cancer Res., 77, 4868, 10.1158/0008-5472.CAN-17-0391 · DOI · Paper page
- Buckarma, 2020, The yap-interacting phosphatase shp2 can regulate transcriptional coactivity and modulate sensitivity to chemotherapy in cholangiocarcinoma, Mol. Cancer Res., 18, 1574, 10.1158/1541-7786.MCR-20-0165 · DOI
- Mettu, 2019, A phase i study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (gdc) in refractory solid tumors, Cancer Chemother. Pharmacol., 83, 1025, 10.1007/s00280-019-03805-6 · DOI
- Evans, 2017, Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer, Ann. Oncol., 28, 354, 10.1093/annonc/mdw607 · DOI
- George, 2021, Phase ii study of 5-fluorouracil, oxaliplatin plus dasatinib (folfox-d) in first-line metastatic pancreatic adenocarcinoma, Oncologist, 26, 825.e1674, 10.1002/onco.13853 · DOI
- Infante, 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral mek inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur. J. Cancer, 50, 2072, 10.1016/j.ejca.2014.04.024 · DOI · Paper page
- Witkiewicz, 2016, Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer, Cell Rep., 16, 2017, 10.1016/j.celrep.2016.07.023 · DOI · Paper page
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
“Src-mediated phosphorylation of KRAS on Tyr32 and Tyr64 alters the protein conformation that inhibit the function of KRAS [87].”
BackgroundTEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Tammaccaro, S. L., Prigent, P., Le Bail, J.-C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J.-C., Veeranagouda, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040553 · Cited by 18
“These kinases modulate KRAS phosphorylation by either signaling on LATS1/2 or by directly acting on YAP1 phosphorylation [17].”
BackgroundIMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
Metadata
- Authors
- Rozengurt, E., & Eibl, G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-10-13
- Volume
- 13
- Issue
- 20
- Pages
- 5126
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3206563978
- Cited by
- 30
- References
- 65
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Institutes of Health (P01CA236585, R21AI156592)
- Veterans Health Administration (I01BX003801)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. https://app.cochat.ai/papers/10.3390/cancers13205126
- The paper
- Rozengurt, E., & Eibl, G. (2021). Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers. https://doi.org/10.3390/cancers13205126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.